Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7426 to 7440 of 7675 results

  1. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development [GID-TA11166] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development [GID-TA11089] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    In development [GID-TA11411] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Technology appraisal guidance
    Published
    27 July 2016

  5. Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]

    In development [GID-TA11580] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development [GID-TA10745] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  7. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development [GID-TA11567] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development [GID-TA11482] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development [GID-TA11475] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development [GID-TA11301] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour (IPG744)

    June 2023: We are aware that the International Journal of Gynecology and Obstetrics has retracted a 2016 paper, which was used in committee decision making for this topic (IPG744). As the evidence base has now changed, it is returning to committee for re-discussion, see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. Once the schedule for this has been confirmed, it will be communicated to stakeholders and published on the NICE website. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).

    Interventional procedures guidance
    Published
    16 November 2022

  12. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development [GID-TA11353] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development [GID-TA11582] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section (IPG515)

    September 2024: We have withdrawn this guidance. This is because the main evidence that the guidance was based on has been retracted by the journal. New NICE interventional procedures guidance is in development and the expected publication date is April 2025. Please see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).

    Interventional procedures guidance
    Published
    27 March 2015

  15. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA802.

    Technology appraisal guidance
    Published
    7 August 2019